ARIKAYCE (amikacin) 

SELF ADMINISTRATION- INHALATION SUSPENSION

Indications for Prior Authorization:

  • Indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy

Patients must meet the following criteria for the indication(s) above:

  • Patient is 18 years of age or older, AND
  • Diagnosis of Mycobacterium avium complex (MAC) lung disease confirmed by chart note documentation, AND
  • Prescribed by or in consultation with an infectious disease specialist or pulmonologist, AND
  • Failure (confirmed by a positive sputum culture) of at least a 6-month trial of a multidrug background regimen therapy at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced, AND
  • Arikayce® should be used with background multidrug regimen (including a macrolide [azithromycin or clarithromycin], ethambutol, and a rifamycin [rifampin or rifabutin])

Dosing: 

  • Inhale 1 vial (590mg/8.4mL) once daily
  • For oral inhalation use only
  • Use Arikayce® vials only with the Lamira Nebulizer System
  • Consider pre-treatment with inhaled bronchodilator in patients with a history of hyperreactive airway disease

Approval: 

  • 1 year

 

 

 

 

 

 

 

Last review date: December 9, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone